Galapagos to present R&D update on 27 March 2009

Mechelen, Belgium; 23 March 2009 – Galapagos NV (Euronext: GLPG) invites analysts, investors and journalists to attend an R&D update meeting in which an overview of the Company’s clinical and pre-clinical pipeline progress will be given.  The meeting will take place at Galapagos headquarters at Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, B-2800 Mechelen, Belgium starting at 11.00 CET on 27 March 2009.
Galapagos management will present the R&D strategy, the latest information on Galapagos’ discovery and development programs and an update to its clinical and pre-clinical portfolio.  Those who wish to attend the meeting in person should confirm their attendance via email to
Galapagos will also hold a conference and live audio webcast of this meeting starting at 11.00 CET on 27 March 2009.  Click here to access the live audio webcast.  To participate in the conference call, please call +32 2290 1608 ten minutes prior to commencement.  A question and answer session will follow the presentation of the results.  The archived webcast also will be available for replay shortly after the live presentation.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases.  It has established risk sharing alliances with GSK, Janssen Pharmaceutica, Eli Lilly and Merck.  Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.  Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  Galapagos currently employs 480 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:
Galapagos NV
Elizabeth Goodwin
Director Investor Relations
Tel: +31 62 291 6240
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.